Breaking Finance News

Zacks Investment Research downgraded AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to Sell in a statement released earlier today.

Zacks Investment Research has downgraded AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) to Sell in a statement released on 9/27/2016.

On Thursday September 15, 2016, Roth Capital released a statement for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) bumped up the target price from $11.25 to $15.00 that suggested an upside of 3.57%.

Boasting a price of $3.85, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) traded 6.35% higher on the day. With the last close up 17.30% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. AcelRx Pharmaceuticals Inc has recorded a 50-day average of $3.41 and a two hundred day average of $3.28. Volume of trade was up over the average, with 503,772 shares of ACRX changing hands over the typical 359,778

Recent Performance Chart

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)

AcelRx Pharmaceuticals Inc has 52 week low of $2.40 and a 52 week high of $5.88 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokerages have issued a research note on the stock. The consensus target price is $7.63 with 1 firm rating the stock a strong buy, 3 firms rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.